Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Washington University School of Medicine
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
University of Maryland, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CHA University
The Second Affiliated Hospital of Shandong First Medical University
Tata Memorial Centre
AHS Cancer Control Alberta
Shandong Cancer Hospital and Institute
First Affiliated Hospital of Zhejiang University
Tongji Hospital
National Health Research Institutes, Taiwan
UNICANCER
Tata Memorial Centre
Gruppo Oncologico del Nord-Ovest
Krankenhaus Nordwest
Georgetown University
Shanghai Zhongshan Hospital
Seoul National University Hospital
The Christie NHS Foundation Trust
University of Michigan Rogel Cancer Center
University of Cincinnati
ASLAN Pharmaceuticals
Huazhong University of Science and Technology
Johannes Gutenberg University Mainz
University of Pisa
Barretos Cancer Hospital
Chinese PLA General Hospital
University of Michigan Rogel Cancer Center
University College, London
University College, London
Asan Medical Center
Gyeongsang National University Hospital
Dana-Farber Cancer Institute